Computational Innovation | Boehringer Ingelheim UK
Pioneering computational innovation in pharmaceutical research & development
At Boehringer Ingelheim, we’re transforming how medicines are discovered and developed by embedding computational biology, artificial intelligence (AI), and data excellence into every step of our innovation pipeline. Computational science is helping us move faster, make smarter decisions, and bring innovative therapies/treatments to patients with unmet medical needs.
How AI and computational science are accelerating drug discovery
Computational science is central to our innovation strategy. It’s not just about adopting new tools—it’s about rethinking how we approach R&D challenges. From identifying new therapeutic concepts (NTCs) to designing better-tolerated, more effective molecules, we’re using data-driven methods to improve outcomes in development.
Our focus spans across several key areas:
NTC discovery and asset maximization: Using computational innovation to help uncover promising drug targets with strong links to human disease.
Biomarker discovery and patient understanding: Enhancing patient stratification and biomarker discovery to improve clinical outcomes.
Safety by design: Predicting and mitigating safety risks early in development.
Molecule design: Leveraging AI to help create high-quality molecules faster.
We’re taking a bold, data-first approach to deepen our understanding of disease biology and therapeutic potential. By combining next-generation analytics with human data and in-silico modeling, we’re building strong evidence packages that link targets to diseases, guide patient selection, and support safety assessments. Collaboration across teams and with external partners is key to unlocking the full value of data.
Watch highlights from the launch of our AI Accelerator in King’s Cross, London, UK, a key milestone in expanding Boehringer Ingelheim’s global Computational Innovation footprint.
Bringing together expertise across science, data and technology, the Accelerator is designed to advance AI-driven discovery research. It reflects our long-term commitment to improving patient outcomes through data-driven science and to accelerating the development of innovative medicines for patients with unmet needs.
Hear from our distinguished speakers including Lord Patrick Vallance, UK Science Minister, and Steve Bates OBE, Executive Chair of the Office for Life Sciences, on shaping the future of the UK’s AI and talent landscape.
Watch highlights from the launch of Boehringer Ingelheim’s AI Accelerator in King’s Cross, London
NP-GB-107603 June 2026